caa a22 4500 475833767 CHVBK 20180406123848.0 cr unu---uuuuu 170329e20001001xx s 000 0 eng 10.1023/A:1007832921391 doi (NATIONALLICENCE)springer-10.1023/A:1007832921391 Isosorbide-2-Mononitrate Reduces the Consequences of Myocardial Ischaemia, Including Arrhythmia Severity: Implications for Preconditioning [Elektronische Daten] [Katalin György, Ágnes Végh, Mohamed Rastegar, Julius Papp, James Parratt] The effects of the intracoronary administration of isosorbide-2-mononitrate (ISMN; 3 μg kg−1 min−1), a major metabolite of isosorbide dinitrate, were examined in chloralose-urethane anaesthetized dogs before and during a 25 min, acute occlusion of the left anterior descending coronary artery. The only significant haemodynamic effects of ISMN administration were a slight (−11 ± 2 mmHg) decrease in arterial blood pressure and a decrease (<12%) in diastolic coronary vascular resistance. Coronary occlusion in the presence of ISMN led to a markedly reduced incidence and severity of ventricular arrhythmias compared to those in control, saline-infused dogs. There were fewer ectopic beats (62 ± 35 versus 202 ± 72; p < 0.05), a lower incidence (25% versus 75%; p < 0.05) and number of episodes (0.7 ± 0.4 versus 4.3 ± 2.1; p < 0.05) of ventricular tachycardia and fewer dogs fibrillated during the ischaemic period (17% versus 82%; p < 0.05). More dogs given ISMN survived the combined ischaemia-reperfusion insult (50% versus 0%; p < 0.05). Changes in ST-segment elevation (recorded by epicardial electrodes) and in the degree of inhomogeneity of electrical activation within the ischaemic area were much less pronounced throughout the occlusion period in dogs given ISMN. These results add weight to the hypothesis that the previously reported antiarrhythmic effects of ischaemic preconditioning, and of the intracoronary administration of nicorandil, involve nitric oxide. Kluwer Academic Publishers, 2000 isosorbide-2-mononitrate nationallicence myocardial ischaemia nationallicence ventricular arrhythmias nationallicence ischaemic preconditioning nationallicence nitric oxide nationallicence reperfusion nationallicence György Katalin Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dóm tér 12, Pf. 115, H-6701, Szeged, Hungary aut Végh Ágnes Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dóm tér 12, Pf. 115, H-6701, Szeged, Hungary aut Rastegar Mohamed Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dóm tér 12, Pf. 115, H-6701, Szeged, Hungary aut Papp Julius Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dóm tér 12, Pf. 115, H-6701, Szeged, Hungary aut Parratt James Department of Physiology and Pharmacology, Strathclyde Institute for Biomedical Sciences, 27 Taylor Street, G4 0NR, Glasgow, UK aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/5(2000-10-01), 481-488 0920-3206 14:5<481 2000 14 10557 https://doi.org/10.1023/A:1007832921391 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007832921391 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- György Katalin Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dóm tér 12, Pf. 115, H-6701, Szeged, Hungary aut NATIONALLICENCE 700 1- Végh Ágnes Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dóm tér 12, Pf. 115, H-6701, Szeged, Hungary aut NATIONALLICENCE 700 1- Rastegar Mohamed Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dóm tér 12, Pf. 115, H-6701, Szeged, Hungary aut NATIONALLICENCE 700 1- Papp Julius Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dóm tér 12, Pf. 115, H-6701, Szeged, Hungary aut NATIONALLICENCE 700 1- Parratt James Department of Physiology and Pharmacology, Strathclyde Institute for Biomedical Sciences, 27 Taylor Street, G4 0NR, Glasgow, UK aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/5(2000-10-01), 481-488 0920-3206 14:5<481 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer